Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, March 21, 2017 ) According to Publisher, the Global Nuclear Medicine Market is valued at $4.42 billion in 2015 and is expected to grow at a CAGR of 10.55 % to reach $8.92 billion by 2022. Rising demand from emerging nations and the growing incidence of cardiovascular ailments and cancers are some of the key factors driving the market growth. Conversely, strict government regulations and competition from conventional diagnostic methods are hampering the market. Furthermore, technological advancements in neurological applications are anticipated to create ample of opportunities for the market in the future.
For more information http://www.reportsweb.com/nuclear-medicine-global-market-outlook-2015-2022
North America is the largest market in terms of revenue in 2015 due to several technological advancements within the region. However, Asia Pacific is poised to grow at a faster pace due to the increasing incidence of neurological and cardiovascular diseases and cancer. Various new products are being launched together with the several technological advancements. Thus, new product launch is the key strategy followed by the players to gain the traction in the market.
Some of the key players in global Nuclear Medicine market are Advanced Accelerator Applications S.A., Ashby Gorman Baker Ltd, Bayer Healthcare, Bracco Imaging S.P.A, Cardinal Health, Digirad, Eczcibasi-Monrol Nuclear Products, GE Healthcare, IBA Molecular Imaging, Lantheus Medical Imaging, Mallinckrodt PLC, Mediso Ltd., Nordion, Inc., Philips Healthcare and Siemens Healthcare.
Applications Covered:
-Therapeutics
-Bone Metastasis
-Endocrine Tumors
-Lymphoma
-Thyroid
-Nephrology
-Cardiology
-Neurology
-Other Therapeutic Applications
-Diagnostics
-Positron emission tomography (PET)
-Single Photon Emission Computed Tomography (SPECT)
Types of Nuclear Medicine Covered:
-Nuclear Medicine Therapeutic Isotopes
-Alpha Emitters
-Brachytherapy
-Beta Emitters
-Nuclear Medicine/Radiopharmaceuticals Diagnostics
-Positron emission tomography (PET) Radiopharmaceuticals
-Single photon emission tomography (SPECT)
Procedure Volumes Covered
-Therapeutic
-Alpha Emitters
-Beta Emitters
-Brachytherapy
-Diagnostics
-Single photon emission tomography (SPECT) Radiopharmaceuticals
-Positron emission tomography (PET) Radiopharmaceuticals
End Users Covered:
-Therapeutic
-Alpha Emitters
-Beta Emitters
-Brachytherapy
-Diagnostics
-Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
-Positron Emission Tomography (PET) Radiopharmaceuticals
Stable Isotopes Covered:
-Sulphur (S-32)
-Oxygen (O-18)
-Nitrogen (N-15)
-Deuterium (D2)
-Carbon (C-13)
-Other Stable Isotopes
Request Sample Copy http://www.reportsweb.com/inquiry&RW0001322819/sample
Regions Covered:
-North America
-US
-Canada
-Mexico
-Europe
-Germany
-France
-Italy
-UK
-Spain
-Rest of Europe
-Asia Pacific
-Japan
-China
-India
-Australia
-New Zealand
-Rest of Asia Pacific
-Rest of the World
-Middle East
-Brazil
-Argentina
-South Africa
-Egypt
12 Company Profiling
12.1 Advanced Accelerator Applications S.A.
12.2 Ashby Gorman Baker Ltd,
12.3 Bayer Healthcare
12.4 Bracco Imaging S.P.A
12.5 Cardinal Health
12.6 Digirad
12.7 Eczcibasi-Monrol Nuclear Products
12.8 GE Healthcare
12.9 IBA Molecular Imaging
12.10 Lantheus Medical Imaging
12.11 Mallinckrodt PLC
12.12 Mediso Ltd.
12.13 Nordion, Inc.
12.14 Philips Healthcare
12.15 Siemens Healthcare
Make an enquiry: http://www.reportsweb.com/inquiry&RW0001322819/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|